Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
Merck
Express Scripts
Boehringer Ingelheim
Julphar
US Department of Justice
UBS
Mallinckrodt

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,394,407

« Back to Dashboard

Which drugs does patent 8,394,407 protect, and when does it expire?

Patent 8,394,407 protects RAYOS and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.
Summary for Patent: 8,394,407
Title:Delayed release tablet with defined core geometry
Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Inventor(s): Vergnault; Guy (Kembs, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:13/428,548
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Device; Use;

Drugs Protected by US Patent 8,394,407

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET ➤ Try a Free Trial
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET ➤ Try a Free Trial
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,394,407

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0309342.4Apr 24, 2003

Non-Orange Book US Patents Family Members for Patent 8,394,407

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,085 Delayed release tablet with defined core geometry ➤ Try a Free Trial
9,186,332 Delayed release tablet with defined core geometry ➤ Try a Free Trial
9,884,021 Delayed release tablet with defined core geometry ➤ Try a Free Trial
8,168,218 Delayed release tablet with defined core geometry ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,394,407

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1631251 ➤ Try a Free Trial
Russian Federation 2391093 ➤ Try a Free Trial
Russian Federation 2005132451 ➤ Try a Free Trial
Portugal 1631251 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Julphar
Citi
McKinsey
UBS
AstraZeneca
Federal Trade Commission
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.